美国退伍军人肾结石患者原发性甲状旁腺功能亢进筛查分析
这项队列研究纳入2008至2013年美国130家退伍军人健康管理机构中7561例肾结石合并高钙血症患者,仅24.8%接受了血清PTH检测,各机构检测率4%至57%不等;717例有生化证据的PHPT患者中189例(26.4%)在结石诊断后2年内接受甲状旁腺切除术。
要点
- 肾结石合并高钙血症患者中仅约四分之一接受了PTH筛查。
- 同时就诊肾内科和泌尿外科或内分泌科与更高PTH检测率相关。
- 有生化证据的PHPT患者中仅26.4%在2年内接受甲状旁腺切除术。
核心结论
- 在退伍军人健康管理机构中,肾结石合并高钙血症患者仅四分之一接受PHPT检测,且机构间检测率差异大。
- 提高临床医生对PHPT筛查指征的认识可能改善评估、检出和治疗并减少复发性肾结石。
研究设计与样本
- 队列研究,获取2008年1月1日至2013年12月31日美国130家VHA机构的退伍军人健康记录。
- 纳入有肾或输尿管结石诊断或操作代码的患者,排除既往有血清PTH检测者。
- 最终队列为7561例肾结石合并高钙血症患者,平均(SD)年龄64.3(12.3)岁,男性7139例(94.4%),白人5673例(75.0%)。
主要发现
- 完成血清PTH检测的患者比例为24.8%(1873/7561)。
- 130家VHA机构的检测率范围为4%至57%。
- PTH检测相关因素包括血钙升高幅度(OR 1.07/0.1 mg/dL >10.5 mg/dL;95%CI 1.05-1.08)和血钙升高次数(OR 1.08/次 >10.5 mg/dL;95%CI 1.06-1.10)。
- 同时就诊肾内科和泌尿外科(OR 6.57;95%CI 5.33-8.10)或内分泌科(OR 4.93;95%CI 4.11-5.93)与PTH检测相关。
- 717例有PHPT生化证据的患者中,189例(26.4%)在结石诊断后2年内接受甲状旁腺切除术。
临床怎么用
- 对肾结石合并高钙血症患者应主动评估PHPT筛查指征,尤其血钙升高明显或多次升高者。
- 多学科(肾内科、泌尿外科、内分泌科)参与可提高PHPT检测率。
- 检出PHPT后应评估甲状旁腺切除术指征以减少复发性结石。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Approximately 3% to 5% of patients with kidney stones have primary hyperparathyroidism (PHPT), a treatable cause of recurrent stones. However, the rate of screening for PHPT in patients with kidney stones remains unknown. OBJECTIVES: To estimate the prevalence of parathyroid hormone (PTH) testing in veterans with kidney stones and hypercalcemia and to identify the demographic, geographic, and clinical characteristics of veterans who were more or less likely to receive PTH testing. DESIGN, SETTING, AND PARTICIPANTS: This cohort study obtained Veterans Health Administration (VHA) health records from the Corporate Data Warehouse for veterans who received care in 1 of the 130 VHA facilities across the United States from January 1, 2008, through December 31, 2013. Historical encounters, medical codes, and laboratory data were assessed. Included patients had diagnostic or procedural codes for kidney or ureteral stones, and excluded patients were those with a previous serum PTH level measurement. Data were collected from January 1, 2006, to December 31, 2014. Data analysis was conducted from June 1, 2019, to January 31, 2020. EXPOSURES: Elevated serum calcium concentration measurement between 6 months before and 6 months after kidney stone diagnosis. MAIN OUTCOMES AND MEASURES: Proportion of patients with a serum PTH level measurement and proportion of patients with biochemical evidence of PHPT who underwent parathyroidectomy. RESULTS: The final cohort comprised 7561 patients with kidney stones and hypercalcemia and a mean (SD) age of 64.3 (12.3) years. Of these patients, 7139 were men (94.4%) and 5673 were white individuals (75.0%). The proportion of patients who completed a serum PTH level measurement was 24.8% (1873 of 7561). Across the 130 VHA facilities included in the study, testing rates ranged from 4% to 57%. The factors associated with PTH testing included the magnitude of calcium concentration elevation (odds ratio [OR], 1.07 per 0.1 mg/dL >10.5 mg/dL; 95% CI, 1.05-1.08) and the number of elevated serum calcium concentration measurements (OR, 1.08 per measurement >10.5 mg/dL; 95% CI, 1.06-1.10) as well as visits to both a nephrologist and a urologist (OR, 6.57; 95% CI, 5.33-8.10) or an endocrinologist (OR, 4.93; 95% CI, 4.11-5.93). Of the 717 patients with biochemical evidence of PHPT, 189 (26.4%) underwent parathyroidectomy within 2 years of a stone diagnosis. CONCLUSIONS AND RELEVANCE: This cohort study found that only 1 in 4 patients with kidney stones and hypercalcemia were tested for PHPT in VHA facilities and that testing rates varied widely across these facilities. These findings suggest that raising clinician awareness to PHPT screening indications may improve evaluation for parathyroidectomy, increase the rates of detection and treatment of PHPT, and decrease recurrent kidney stone disease.
引用
- Ganesan C, Weia B, Thomas IC, et al. Analysis of Primary Hyperparathyroidism Screening Among US Veterans With Kidney Stones. JAMA Surg. 2020. PMID: 32725208. doi:10.1001/jamasurg.2020.2423
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。